CJC-1295 without DAC + Ipamorelin

A blend of CJC-1295 without DAC and Ipamorelin in a single vial, 5mg of each. Each component is described on its own product page.

The pairing is a two-receptor combination rather than two versions of one thing, and that is the substantive fact about it. CJC-1295 without DAC is a 29-residue analogue of growth hormone releasing factor and acts at the GHRH receptor, a class B secretin-family G-protein-coupled receptor that signals through adenylyl cyclase and cyclic AMP. Ipamorelin is an unrelated pentapeptide built on alpha-aminoisobutyric acid and two D-amino acids, and acts at the growth hormone secretagogue receptor type 1a, a class A rhodopsin-family receptor that signals through phospholipase C and calcium. Two different receptor families, two different second messengers.

The two also differ in how they resist breakdown. The releasing-factor analogue relies on four engineered substitutions, chiefly a D-alanine at position two that blocks dipeptidyl peptidase IV cleavage. The pentapeptide relies on a non-proteinogenic residue at position one, two D-configured aromatic residues, and a C-terminal amide, which together make it a poor substrate for ordinary peptidases.

No published study characterises this two-component mixture as an entity. Citations shown on this page are papers about the individual components and are labelled as such.

Because the vial carries two compounds of very different size, roughly 3,368 daltons against roughly 712, a single spectroscopic reading cannot report both and identity work requires a separation method. As with every blend in the catalogue, the label states a combined mass, so a per-milligram figure is not comparable with the same figure for a single compound and none is published.